Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs).
CD25
CML modeling
blast crisis CML
iPSC
single-cell transcriptomics
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
12 02 2023
12 02 2023
Historique:
received:
29
12
2022
revised:
07
02
2023
accepted:
08
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
To model CML progression in vitro and generate a blast crisis (BC-CML) model in vitro in order to identify new targets. Three different CML-derived iPSC lines were mutagenized with the alkylating agent ENU on a daily basis for 60 days. Cells were analyzed at D12 of hematopoietic differentiation for their phenotype, clonogenicity, and transcriptomic profile. Single-cell RNA-Seq analysis has been performed at three different time points during hematopoietic differentiation in ENU-treated and untreated cells. One of the CML-iPSCs, compared to its non-mutagenized counterpart, generated myeloid blasts after hematopoietic differentiation, exhibiting monoblastic patterns and expression of cMPO, CD45, CD34, CD33, and CD13. Single-cell transcriptomics revealed a delay of differentiation in the mutated condition as compared to the control with increased levels of iPSCs are a valuable tool to model CML progression and to identify new targets. Here, we show the relevance of CD25 identified in the iPSC model as a marker of CML progression.
Identifiants
pubmed: 36831265
pii: cells12040598
doi: 10.3390/cells12040598
pmc: PMC9953961
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Oncology (Williston Park). 1987 Sep;1(7):35-40, 48-9, 52
pubmed: 3152810
Leukemia. 2010 Nov;24(11):1823-33
pubmed: 20861912
Cancer Res. 2008 Apr 15;68(8):2576-80
pubmed: 18413724
Cancer Cell. 2002 Aug;2(2):117-25
pubmed: 12204532
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):203-7
pubmed: 9874796
Oncotarget. 2011 Sep;2(9):713-27
pubmed: 21946665
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Oncogene. 1999 Apr 29;18(17):2676-80
pubmed: 10348341
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W305-11
pubmed: 19465376
Clin Cancer Res. 2016 Apr 15;22(8):2051-61
pubmed: 26607600
J Exp Med. 2016 Jul 25;213(8):1513-35
pubmed: 27377587
J Gene Med. 2021 Jul;23(7):e3339
pubmed: 33829606
Leuk Lymphoma. 1993;11 Suppl 1:11-5
pubmed: 8251885
Oncogene. 2005 Jun 2;24(24):3914-22
pubmed: 15750625
N Engl J Med. 2003 Oct 9;349(15):1451-64
pubmed: 14534339
Nat Protoc. 2007;2(10):2366-82
pubmed: 17947979
Blood. 2003 Jun 1;101(11):4583-8
pubmed: 12576338
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2794-9
pubmed: 16477019
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Blood. 2011 Sep 29;118(13):3657-60
pubmed: 21791426
Blood. 2012 Jun 28;119(26):6234-42
pubmed: 22592606
Am J Hematol. 2010 Jul;85(7):482-6
pubmed: 20575039
J Med Life. 2015 Oct-Dec;8(4):502-8
pubmed: 26664479
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
pubmed: 12011421
Exp Hematol. 2017 Sep;53:48-58
pubmed: 28602946
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
Blood. 2003 Oct 1;102(7):2632-7
pubmed: 12829601
Am J Hematol. 2014 May;89(5):547-56
pubmed: 24729196
Blood. 2013 May 16;121(20):4175-83
pubmed: 23543457
Exp Hematol. 2013 Apr;41(4):335-45.e3
pubmed: 23287417
Blood. 2011 Nov 17;118(20):5565-72
pubmed: 21931114
Blood. 2001 Apr 1;97(7):2084-90
pubmed: 11264175
Blood. 2002 Jan 1;99(1):319-25
pubmed: 11756187
Leukemia. 2008 Oct;22(10):1969-72
pubmed: 18401418
J Clin Invest. 2010 Jul;120(7):2254-64
pubmed: 20592475
J Clin Oncol. 2006 Nov 20;24(33):e51-2
pubmed: 17114651
Stem Cell Res. 2016 Sep;17(2):235-237
pubmed: 27879209
Blood. 2014 Apr 17;123(16):2540-9
pubmed: 24574458
Blood. 2014 Jun 19;123(25):3951-62
pubmed: 24778155
Blood Adv. 2020 Oct 27;4(20):5118-5132
pubmed: 33085758